How to treat parkinson's disease in 2013

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 13, Issue 1, 2013, Pages 93-96

  Worth, Paul F ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENSERAZIDE PLUS LEVODOPA; BOTULINUM TOXIN; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DESIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MACROGOL; MONOAMINE OXIDASE B INHIBITOR; NORTRIPTYLINE; PRAMIPEXOLE; RASAGILINE; RIVASTIGMINE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL; NEUROPROTECTIVE AGENT;

ADD ON THERAPY; ARTICLE; BABINSKI REFLEX; BRADYKINESIA; CONSTIPATION; DEMENTIA; DEPRESSION; DRUG ABSORPTION; DRUG EFFICACY; DYSKINESIA; HUMAN; LIVER TOXICITY; MONOTHERAPY; PARKINSON DISEASE; PSYCHOSIS; QUALITY OF LIFE; SEDATION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; KINESIOTHERAPY; METHODOLOGY; REVIEW; TREATMENT OUTCOME;

EXERCISE THERAPY; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84884529657     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.13-1-93     Document Type: Article

References (20)

1. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
2. National Collaborating Centre for Chronic Conditions. Parkinson's disease: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians, 2006.
3. MacMahon DG, Thomas S. Practical approach to quality of life in Parkinson's disease: The nurse's role. J Neurol 1998;245(Suppl 1):S19-22.
4. Hobson P, Meara J, Ishihara-Paul L. The estimated life expectancy in a community cohort of Parkinson's disease patients with and without dementia, compared with the UK population. J Neurol Neurosurg Psychiatry 2010;81:1093-8.
5. Grosset D, Taurah L, Burn DJ et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007;78:465-9.
6. Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508.
7. Ku S, Glass GA. Age of Parkinson's disease onset as a predictor for the development of dyskinesia. Mov Disord 2010;25:1177-82.
8. Stacy M, Galbreath A. Optimizing longterm therapy for Parkinson disease: levodopa, dopamine agonists, and treatmentassociated dyskinesia. Clin Neuropharmacol 2008;31:51-6.
9. Vlaar A, Hovestadt A, van Laar T, Bloem BR. The treatment of early Parkinson's disease: levodopa rehabilitated. Pract Neurol 2011;11:145-52.
10. Voon V, Sohr M, Lang AE et al. Impulse control disorders in Parkinson disease: A multicenter case-control study. Ann Neurol 2011;69:986-96.
11. Scottish Intercollegiate Guidelines Network. Diagnosis and pharmacological management of Parkinson's disease, SIGN guideline No. 113. Edinburgh: SIGN, 2010.
12. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005;20:1502-7.
13. Olanow CW, Rascol O, Hauser RA et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-78.
14. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58.
15. Rascol O, Brooks DJ, Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): A randomised, doubleblind, parallel-group trial. Lancet 2005;365:947-54.
16. Bonifati V, Meco G. New, selective catechol- O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol Ther 1999;81:1-36.
17. Reichmann H, Boas J, Macmahon D et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand 2005;111:21-8.
18. Seppi K, Weintraub D, Coelho M et al. The Movement Disorder Society evidencebased medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S42-80.
19. Trenkwalder C, Kies B, Rudzinska M et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-9.
20. Honig H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74.